Shruti Bhat PhD, MBA, Lean Six Sigma Black Belt
  • Home
  • About Shruti
  • Consulting
  • Workshops
  • Patents
  • Articles
    • Case Studies
    • Innovation Portfolio Development & Patents
    • Drugs-in-the- making
    • Culture Change & Business Transformation
    • Operational Excellence, Quality & Continuous Improvement
  • Books
  • Digital
  • Blog
  • Videos
  • Contact

Clinical research updates on new drugs

2/12/2010

0 Comments

 
FDA does not approve Ofirmev due to manufacturing site issues.
Reuter’s reported, "A pain and fever drug," called Ofirmev (intravenous acetaminophen), "being developed by Cadence Pharmaceuticals was not approved by federal regulators because of manufacturing problems at a facility where the drug is made, the company said Thursday." The FDA said it will not approve the drug until the issues are resolved. "Cadence said the FDA inspected a third party manufacturing facility on Friday," and the company "plans to meet with the FDA to make sure the problems have been addressed."  It is stated further that, the FDA did not cite any safety or efficacy issues for the drug or require any additional studies to be conducted prior to approval.  

FDA approves heat-stable version of Norvir.
Abbott Laboratories reported that it received Food and Drug Administration approval for a heat-stable version of the HIV treatment Norvir [ritonavir]." The approval is for a new formulation of the drug that "allows it to be stored at room temperature rather than in a refrigerator."  

Taspoglutide may reduce sugar levels when compared with or added to other treatments.
Roche Holding AG declared  results from five late-stage clinical trials show that its experimental diabetes drug taspoglutide reduced blood sugar levels when compared with or added to widely prescribed treatments." Roche said in a statement that the drug met the main goal of studies comparing it to Lantus (insulin glargine injection), Byetta (exenatide injection) and Januvia (sitagliptin), as well as trials where it was combined with metformin and against placebo. Additionally, taspoglutide was found to be generally well tolerated in all five trials, and the most frequently reported side effects were nausea and vomiting.  

Few women taking tamoxifen for breast cancer prevention.
A study, appearing in the February 2010 edition of Cancer Epidemiology, Biomarkers & Prevention,Gardner) reported that, "despite the fact that experts have known since 1998 that tamoxifen can cut the risk of developing breast cancer by almost 50 percent," a recent study found that "only a tiny fraction of women at high risk of developing breast cancer take tamoxifen to prevent the disease." Looking at data on about 10,000 women from 2000 and 2005,. Researchers found that "only about 0.2 percent of US women aged 40 to 79 took tamoxifen to prevent breast cancer" in 2000. "In 2005, the prevalence was even lower -- only 0.08 percent." Researchers "did not say specifically how many of the women taking tamoxifen were at high risk for breast tumors."  

Tamoxifen use linked to lower cognitive test scores.
According to a study appearing in the February Journal of Clinical Oncology, tamoxifen appears to affect cognitive abilities, including some types of memory. After a year of taking tamoxifen (Nolvadex), women in the study scored lower on tests of verbal memory functioning and other cognitive skills than did women taking another breast cancer drug, exemestane (Aromasin). Still, researchers "emphasized that it's important to keep the study results in perspective, noting the life-saving benefits of tamoxifen. 

Twice weekly etanercept may provide benefits for skin but not joints.
According to a study published Feb. 2 in the BMJ, "twice weekly treatment with 50 mg of etanercept appears to be superior to once weekly treatment for the clearance of skin lesions in patients with psoriasis and psoriatic arthritis," but "there was no significant difference between the two etanercept regimens in the treatment of joint symptoms." Researchers arrived at those conclusions after studying "752 patients with both psoriasis and psoriatic arthritis who were randomly assigned to receive etanercept 50 mg twice weekly (n=379) or 50 mg once weekly (n=373) for 12 weeks by subcutaneous injection."  
Follow Shruti on Twitter, Facebook, YouTube, LinkedIn
0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    Shruti Bhat, global leader in business turnaround, operational excellence and continuous improvement

    New Book Released!

    top ten strategic decision-making tools for operational excellence

    Shruti's YouTube Channel ...

    Picture

    Blog Categories

    All
    3D Printing
    5S
    Agile
    Artificial Intelligence
    Automation
    Balanced Score Card
    Biotechnology
    Books
    Business Turnaround
    Case Studies
    Change Management
    Chemical Industry
    CMMI
    Continuous Improvement
    Design Thinking
    Digitalization
    Drug Delivery
    External News Links
    Food Industry
    Hall Of Fame
    Healthcare
    Hoshin Kanri
    HR Development
    Innovation
    ISO
    Just In Time
    Kaizen
    Leadership
    LEAN
    Lean Six Sigma
    Life Sciences
    Machine Learning
    Manufacturing
    Medical Devices
    Mistake Proofing
    Motivational Cards
    Nanotechnology
    Operations
    Packaging
    Patents
    Personal Products
    Process Improvement
    Product Development
    Productivity Increase
    QbD
    Quality Management
    Robotics
    Scrum
    Service Industry
    Six Sigma
    Strategy
    Supply Chain Logistics
    Telecom Industry
    TQM
    Videos
    Voice Of Customer
    Workshops

    Shruti's books...

    Picture
    shruti bhat, business process management, continuous improvement
    kaizen for pharmaceutcials, medical devices and biotech industry book by Dr Shruti Bhat
    Book on Continuous improvement tools by Dr Shruti Bhat
    kaizen for leaders, continuous process improvement tool to increase profit and organizational excellence by shruti bhat
    kaizen, shruti bhat, continuous improvement, quality, operations management
    Picture
    how to overcome challenges of creating effective teams
    how to lead a successful business transformation

    ​Micro-Learning
    ​Partner

    Picture

    Publishing Partner

    fast read books, business management books, health and wellness books, spiritual guidance books, best online book store

    Wellness
    ​Partner

    Picture
© Copyright 1992- 2022 Dr. Shruti Bhat ALL RIGHTS RESERVED.
See Terms and Conditions for details on this site usage.
SHRUTI BHAT, CONTACT
Click to connect.
Created by Macro2Micro Media